In Australia, the Pharmaceutical Benefits Scheme (PBS) subsidizes a range of medications for managing DKD, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), sodium-glucose co-transporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (3, 35). The gene discussed is ACE; the disease is diabetic kidney disease.